JPI 289

Drug Profile

JPI 289

Alternative Names: JI-6289; JPI-289

Latest Information Update: 07 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jeil Pharmaceutical
  • Class Anti-ischaemics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 01 Nov 2016 Phase-II clinical trials in Stroke in South Korea (IV) (NCT03062397)
  • 26 Nov 2013 Phase-I clinical trials in Stroke (in volunteers) in South Korea (IV)
  • 19 Nov 2013 JPI 289 is available for licensing as of 19 Nov 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top